Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Hyatt Hotels Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Hyatt Hotels Corporation trades at $172.22 (market cap $16.27B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Hyatt Hotels Corporation pays a 0.35% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | H | |
|---|---|---|
Market Cap | $29.60B | $16.27B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $202.09 |
52-Week Low | $205.48 | $135.42 |
Enterprise Value | $27.56B | $20.17B |
Dividend Yield | — | 0.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Hyatt Hotels Corp (H) trades at $178.25, up 4.8% over 24 hours, near its 52-week high of $206.86. The stock shows a bearish technical signal despite recent earnings beats, with Q2 2026 EPS of $1.12 surpassing the $0.913 estimate. Fundamentals reveal a high P/E ratio of 213.14 and thin net income margin of 1.1%, though revenue grew to $7.10B in 2025. Analyst consensus is a 'Hold' with a $199.55 price target, while recent news highlights valuation concerns amid fee growth and RevPAR gains.
Outlook is mixed: strong fee growth and a record pipeline support expansion, but high valuation, project delays, and debt pose risks. The stock offers potential from operational momentum, yet investors face headwinds from regional weakness and rich multiples. Net cash flow turned negative in 2025, underscoring financial pressure despite EBITDA growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
